Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving ≥3 therapy lines in post-CAR-T era

References

• Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604–616.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program 2016 [Internet]. [cited 2021 Jan 4]. Available from: https://seer.cancer.gov/csr/1975_2016/browse_csr.php?sectionSEL=19&pageSEL=sect_19_table.26
   Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040–2045.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808.
   PubMed Web of Science ®Google Scholar
• Koh JJ, Lim ST, Sultana R, et al. Predictors of early vs late diffuse large B cell lymphoma (DLBCL) relapses in the rituximab era. J Clin Oncol. 2018;36(15_suppl):E19553–e19553.
   Web of Science ®Google Scholar
• Raut LS, Chakrabarti PP. Management of relapsed–refractory diffuse large B cell lymphoma. South Asian J Cancer. 2014;3(1):66–70.
   PubMedGoogle Scholar
• Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:498–505.
   PubMed Web of Science ®Google Scholar
• Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003;102(6):1989–1996.
   PubMed Web of Science ®Google Scholar
• Van Den Neste E, Schmitz N, Mounier N, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2017;52(2):216–221.
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Sehn LH. Management of relapsed/refractory DLBCL. Best Pract Res Clin Haematol. 2018;31(3):209–216.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Chalhoub B, Suzan F, et al. Outcome of elderly patients with aggressive non-Hodgkin’s lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: a low probability of cure. Leuk Lymphoma. 2004;45(7):1391–1394.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Blum KA, Kahl BS, et al. Beyond RCHOP: a blueprint for diffuse large B cell lymphoma research. JNCI J Natl Cancer Inst. 2016;108(12):djw257.
   Web of Science ®Google Scholar
• Food and Drug Administration. Yescarta (axicabtagene ciloleucel): highlights of prescribing information. 2017. [cited 2021 Apr 12]. Available from: https://www.fda.gov/media/108377/download
   Google Scholar
• Food and Drug Administration. Kymriah (tisagenlecleucel): highlights of prescribing information. 2017. [cited 2021 Jan 4]. Available from: https://www.fda.gov/media/107296/download
   Google Scholar
• Food and Drug Administration. Breyanzi (lisocabtagene maraleucel): highlights of prescribing information. 2021. [cited 2021 Apr 12]. Available from: https://packageinserts.bms.com/pi/pi_breyanzi.pdf
   Google Scholar
• Food and Drug Administration. Polivy (polatuzumab vedotin-piiq): highlights of prescribing information. 2019. [cited 2021 Jan 4]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf
   Google Scholar
• Food and Drug Administration. Xpovio (selinexor): highlights of prescribing information. 2019. [cited 2021 Jan 4]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212306s001lbl.pdf
   Google Scholar
• Food and Drug Administration. Monjuvi (tafasitamab-cxix): highlights of prescribing information. 2020. [cited 2021 Jan 4]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761163s000lbl.pdf
   Google Scholar
• Morrison VA, Shou Y, Bell JA, et al. Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA. Future Oncol. 2019;15(9):1021–1034.
   PubMed Web of Science ®Google Scholar
• Mytelka DS, Li L, Stafkey-Mailey D, et al. Treatment patterns and outcomes among patients with high-intermediate/high-risk diffuse large B-cell lymphoma in the USA. Hematology. 2015;20(8):442–448.
   PubMed Web of Science ®Google Scholar
• Danese MD, Griffiths RI, Gleeson ML, et al. Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy. Leuk Lymphoma. 2017;58(5):1094–1104.
   PubMed Web of Science ®Google Scholar
• IQVIA. IQVIA PharMetrics Plus – Fact Sheet [Internet]. 2020 [cited 2021 Feb 18]. Available from: https://www.iqvia.com/library/fact-sheets/iqvia-pharmetrics-plus
   Google Scholar
• Lymphoma Research Foundation. Understanding transformed lymphomas. 2020. [cited 2021 Jan 4]. Available from: https://lymphoma.org/wp-content/uploads/2020/11/LRF-Transformed-Lymphoma_Factsheet_110920-1.pdf
   Google Scholar
• Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.1.2020 - January 22, 2020 © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
   Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682.
   PubMed Web of Science ®Google Scholar
• Yang X, Laliberté F, Germain G, et al. PF321: real-world treatment patterns of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) in the United States (US). HemaSphere. 2019;3(S1):113–116.
   PubMed Web of Science ®Google Scholar
• Ayers EC, Margolis D, Landsburg DJ. Real world outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma receiving palliative intent therapies. Clin Lymphoma Myeloma Leuk. 2020;20(10):661–667.
   PubMed Web of Science ®Google Scholar
• Radford J, White E, Castro FA, et al. Treatment patterns and outcomes in patients with relapsed or refractory diffuse large B-cell lymphoma: experience from a single UK centre. Blood. 2019;134(Suppl 1):2917. doi:.
   Web of Science ®Google Scholar
• Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2016;51(1):51–57.
   PubMed Web of Science ®Google Scholar
• Hou K, Yu Z, Jia Y, et al. Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: a single-arm meta-analysis. Crit Rev Oncol Hematol. 2020;152:103010.
   PubMed Web of Science ®Google Scholar
• Jalbert JJ, Arnason JE, Ge W, et al. Real-world treatment patterns among patients with diffuse large B-cell lymphoma (DLBCL) treated with CD19-directed chimeric antigen receptor T-cell therapy (CAR T). J Clin Oncol. 2020;38(15):EP1269.
   Google Scholar
• Klink AJ, Nabhan C, Lee CH, et al. Real-world management and outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma treated in the United States. J Clin Pathways. 2020;6(1):44–53.
   Google Scholar
• Chien HC, Morreall D, Patil V, et al. Real-world practice patterns and outcomes in veterans with relapsed/refractory diffuse large B-cell lymphoma. Future Oncol. 2021;17:411–422.
   PubMed Web of Science ®Google Scholar
• Ren J, Asche CV, Shou Y, et al. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA. J Comp Eff Res. 2019;8(6):393–402.
   PubMed Web of Science ®Google Scholar
• Purdum A, Tieu R, Reddy SR, et al. Direct costs associated with relapsed diffuse large B-cell lymphoma therapies. The Oncol. 2019;24(9):1229–1236.
   PubMed Web of Science ®Google Scholar
• Yun HD, Dossul T, Bernal-Mizrachi L, et al. Referral patterns and clinical outcomes for transplant-eligible lymphoma and myeloma patients evaluated at an urban county hospital. J Stem Cell Res Ther. 2016;6:328.
   PubMedGoogle Scholar
• Majhail NS, Nayyar S, Santibanez ME, et al. Racial disparities in hematopoietic cell transplantation in the United States. Bone Marrow Transplant. 2012;47(11):1385–1390.
   PubMed Web of Science ®Google Scholar
• Mitchell JM, Conklin EA. Factors affecting receipt of expensive cancer treatments and mortality: evidence from stem cell transplantation for leukemia and lymphoma. Health Serv Res. 2015;50(1):197–216.
   PubMed Web of Science ®Google Scholar
• Broder MS, Ma Q, Yan T, et al. Economic burden of neurologic toxicities associated with treatment of patients with relapsed or refractory diffuse large B-cell lymphoma in the United States. Am Health Drug Benefits. 2020;13(5):192–199.
   PubMed Web of Science ®Google Scholar
• Sermer D, Batlevi C, Palomba ML, et al. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Adv. 2020;4(19):4669–4678.
   PubMed Web of Science ®Google Scholar
• Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol. 2019;10:2040620719841581.
   Web of Science ®Google Scholar
• Kochenderfer JN, Somerville RPT, Lu T, et al. Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol Ther. 2017;25(10):2245–2253.
   PubMed Web of Science ®Google Scholar
• Di Rocco A, Di Rocco A, Farcomeni A, et al. Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients: a retrospective analysis of eligibility criteria for CAR-T cell therapy. Blood. 2019;134(Suppl 1):2888.
   Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.
   PubMed Web of Science ®Google Scholar
• Paillassa J, Di Blasi R, Chevret S, et al. CD19 CAR T-cell therapy in patients with relapse/refractory DLBCL: retrospective analysis of the eligibility criteria. Blood. 2019;134(Suppl 1):2887.
   Web of Science ®Google Scholar
• Smedby KE, Harrysson S, Ekberg S, et al. Evaluation of eligibility for CAR-T cell therapy in a population-based cohort of 3550 patients with incident diffuse large B-cell lymphoma (DLBCL) in Sweden. Blood. 2020;136(Suppl 1):38–39. doi:.
   Web of Science ®Google Scholar
• Kansagra A, Farnia S, Majhail N. Expanding access to chimeric antigen receptor T-cell therapies: challenges and opportunities. Am Soc Clin Oncol Educ Book. 2020;40:1–8.
   PubMedGoogle Scholar
• Jacobson CA, Farooq U, Ghobadi A. Axicabtagene ciloleucel, an anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma: practical implications for the community oncologist. Oncologist. 2020;25(1):e138–e146.
   PubMed Web of Science ®Google Scholar
• Strati P, Nastoupil LJ, Westin J, et al. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(16):3943–3951.
   PubMed Web of Science ®Google Scholar
• Vitale C, Strati P. CAR T-cell therapy for B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences. Front Oncol. 2020;10:849.
   PubMed Web of Science ®Google Scholar
• Kilgore KM, Mohammadi I, Schroeder A, et al. Medicare patients receiving chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma: a first real-world look at patient characteristics, healthcare utilization and costs. Blood. 2019;134(Suppl 1):793.
   PubMed Web of Science ®Google Scholar
• Halwani AS, Chien H-C, Morreall DK, et al. Survival patterns in patients with relapsed or refractory diffuse large B cell lymphoma: treatment trajectories and responses after the first relapse. Blood. 2019;134(Suppl 1):1622.
   Web of Science ®Google Scholar